Vaccines in cancer: GVAX, a GM-CSF gene vaccine (Q36198632)

12 August 2017

1 reference

title

Vaccines in cancer: GVAX, a GM-CSF gene vaccine (English)

1 reference

12 August 2017

John Nemunaitis

1

1 reference

12 August 2017

publication date

1 June 2005

1 reference

Expert Review of Vaccines

12 August 2017

published in

1 reference

12 August 2017

volume

4

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

259-274

1 reference

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Lung cancer vaccines and gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

A comparative review of colony-stimulating factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Origin, maturation and antigen presenting function of dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Role of hematopoietic growth factors/flt3 ligand in expansion and regulation of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Mouse CD1-specific NK1 T cells: development, specificity, and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

NKT cells - conductors of tumor immunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Angiostatin-mediated suppression of cancer metastases by primary neoplasms engineered to produce granulocyte/macrophage colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Interleukin 7 induces CD4+ T cell-dependent tumor rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Transforming growth factor-beta in disease: the dark side of tissue repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

The TGF-beta family of growth and differentiation factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Local production of TGF beta1 inhibits cerebral edema, enhances TNF-alpha induced apoptosis and improves survival in a murine glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

TGF beta 1 and TGF beta 2 are potential growth regulators for medulloblastomas, primitive neuroectodermal tumors, and ependymomas: evidence in support of an autocrine hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

The role of transforming growth factor beta in glioma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor beta 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

From receptor to nucleus: the Smad pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

TGF-beta signalling from cell membrane to nucleus through SMAD proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Enhanced expression of transforming growth factor‐β and its type‐I and type‐II receptors in human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

TGF-B2 and soluble p55 TNFR modulate VCAM-1 expression in glioma cells and brain derived endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Transforming growth factor-beta inhibits interferon-gamma secretion by lymphokine-activated killer cells stimulated with tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Cytokine Gene Therapy with Interleukin-2-Transduced Fibroblasts: Effects of IL-2 Dose on Anti-Tumor Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Inhibition of PKR activation by the proline-rich RNA binding domain of the herpes simplex virus type 1 Us11 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

GM-CSF-based cellular vaccines: a review of the clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Adjuvant specific active lung cancer immunotherapy trials. Tumor-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

Deactivation of macrophages by transforming growth factor-β

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.259

21 January 2018

Identifiers

DOI

10.1586/14760584.4.3.259

1 reference

12 August 2017

1 reference